scholarly journals Expression of interferon-alpha/beta receptor protein in liver of patients with hepatitis C virus-related chronic liver disease

2005 ◽  
Vol 11 (25) ◽  
pp. 3962 ◽  
Author(s):  
Xiang-Wei Meng
1991 ◽  
Vol 13 ◽  
pp. S40-S41
Author(s):  
S. Magrin ◽  
A. Craxì ◽  
C. Fabiano ◽  
G. Fiorentino ◽  
P. Almasio ◽  
...  

1993 ◽  
Vol 41 (3) ◽  
pp. 247-250
Author(s):  
Xing Li ◽  
Norio Hayashi ◽  
Nobukazu Yuki ◽  
Kazuhiro Katayama ◽  
Akinori Kasahara ◽  
...  

Blood ◽  
1997 ◽  
Vol 90 (3) ◽  
pp. 1315-1320 ◽  
Author(s):  
Simone Cesaro ◽  
Maria Grazia Petris ◽  
Flavio Rossetti ◽  
Riccardo Cusinato ◽  
Corrado Pipan ◽  
...  

Abstract Sera of 658 patients who had completed treatment for pediatric malignancy were analyzed by a second-generation enzyme-linked immunosorbent assay and recombinant immunoblot assay test to assess the prevalence of hepatitis C virus (HCV)-seropositivity. All HCV-seropositive patients underwent detailed clinical, laboratory, virologic, and histologic study to analyze the course of HCV infection. One hundred seventeen of the 658 patients (17.8%) were positive for HCV infection markers. Among the 117 anti-HCV+ patients, 41 (35%) were also positive for markers of hepatitis B virus infection with or without delta virus infection markers, 91 (77.8%) had previously received blood product transfusions, and 25 (21.4%) showed a normal alanine aminotransferase (ALT) level during the last 5-year follow-up (11 of them never had abnormal ALT levels). The remaining 92 patients showed ALT levels higher than the upper limit of normal range. Eighty-one of 117 (70%) anti-HCV+ patients were HCV-RNA+, with genotype 1b being present in most patients (54%). In univariate analysis, no risk factor for chronic liver disease was statistically significant. In this study, the prevalence of HCV infection was high in patients who were treated for a childhood malignancy. In about 20% of anti-HCV+ patients, routes other than blood transfusions are to be considered in the epidemiology of HCV infection. After a 14-year median follow-up, chronic liver disease of anti-HCV+ positive patients did not show progression to liver failure.


Infection ◽  
1994 ◽  
Vol 22 (3) ◽  
pp. 183-186 ◽  
Author(s):  
M. Coltorti ◽  
Nicola Caporaso ◽  
Filomena Morisco ◽  
Rosalba Suozzo ◽  
M. Romano ◽  
...  

Author(s):  
João Manuel Silva ◽  
Mário Jorge Silva ◽  
Filipe Calinas ◽  
Paulo Jorge Nogueira

<b><i>Introduction:</i></b> Liver cirrhosis is a prevalent disease in Portugal. Recent changes in alcohol consumption, as well as the wide use of direct-acting antivirals for hepatitis C since 2015, may be contributing to changes in the national burden of liver cirrhosis in the last few years. <b><i>Objectives:</i></b> We aim to characterize the burden of cirrhosis in Portugal between 2010 and 2017. <b><i>Patients and Methods:</i></b> We analyzed all hospital admission episodes due to cirrhosis in Portugal Mainland between 2010 and 2017, registered in the national Diagnosis-Related Group database, according to etiology of cirrhosis. We also analyzed data on mortality and potential years of life lost from liver cirrhosis and chronic liver disease, retrieved from Statistics Portugal (National Institute for Statistics). <b><i>Results:</i></b> Between 2010 and 2017, a total of 51,438 admissions for liver cirrhosis occurred in Portugal. The annual number of admissions decreased (<i>p</i> = 0.044) during the analyzed period. The most frequent cause of cirrhosis was alcoholic liver disease, present in 78.9% of all admissions (<i>n</i> = 40,595), followed by chronic hepatitis C virus infection, present in 11.3% (<i>n</i> = 5,823). A male predominance was identified in the admissions for every analyzed cause of cirrhosis. Annual admissions for alcoholic cirrhosis remained stable (<i>p</i> = 0.075) during the 8-year period. The same stable tendency was observed in the number of admissions for cirrhosis caused by hepatitis C virus (<i>p</i> = 0.861) and alcohol plus hepatitis C virus infection (<i>p</i> = 0.082), although these admissions for hepatitis C-related cirrhosis increased until 2014–2015 and steadily decreased thereafter. Annual deaths due to liver cirrhosis and chronic liver disease decreased from 1,357 in 2010 to 1,038 in 2017 (<i>p</i> = 0.002). The number of potential years of life lost decreased as well in the period (<i>p</i> = 0.001). <b><i>Conclusion:</i></b> The burden of cirrhosis, evaluated by hospital admissions, mortality, and potential years of life lost, decreased in Portugal between 2010 and 2017.


Sign in / Sign up

Export Citation Format

Share Document